[Skip to the reading](#reading) [Care costs & choices](/) New York · A reading guide [Chapters ↓](#chapter-index) [Opening map](/) / GHK-Cu & the evidence GHK-Cu & the evidence # Read the skin claim and the injection claim apart. GHK-Cu has a short chain of three tiny parts, the same kinds of parts used to make proteins, holding a copper atom. An atom is a tiny particle of a substance; here, that substance is the metal copper. Skin products may call GHK-Cu copper tripeptide-1; “tripeptide” means that its chain has three parts. Ask whether the offer is for a skin product or a shot. Research about a cream cannot tell you whether an injection helps. ## What approval does the proposed form have? FDA is short for the Food and Drug Administration, the U.S. agency that reviews medicines. This chapter uses research and FDA information checked on September 30, 2026. GHK-Cu medicines had no FDA approval on September 30, 2026, regardless of their form or intended use. A skin cosmetic A cosmetic sold just to improve appearance generally needs no FDA approval before sale; colour additives are an exception. A promise to change how skin works is different: the FDA gives making skin produce more collagen as an example of a drug claim. Collagen is a protein that helps support skin. Ask which kind of claim is being made for your product; the word “wrinkle” alone does not explain it. Pharmacy-made forms without a shot The FDA list updated May 14, 2026 places GHK-Cu forms that are not injected in category 1: ingredients still being evaluated for pharmacy-made medicines. While it reviews those ingredients, the FDA generally plans to hold off on action against pharmacies that meet its policy’s conditions. A category 1 entry does not give approval or establish that a proposed use is lawful. Ask the prescriber and pharmacy which conditions apply to the proposed medicine and how they meet each one. The linked FDA policy is where to check their explanation. Injection Groups had asked the FDA to consider GHK-Cu for use in pharmacy-made injections, then took those requests back. That is what “nominated but withdrawn” means on the FDA page whose “current” date reads April 22, 2026; it is not approval or clearance. The FDA still lists its safety concerns beside the injection entry. For shots, the FDA is concerned that clumps or impurities could cause an immune reaction, with too little information from people to judge safety. An immune reaction is the body’s defence system responding to the material. ## What the research can and cannot tell you - [FDA’s concerns about GHK-Cu shots](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) Read the injection entry together with its safety concerns; a withdrawn request does not remove those concerns. - [FDA’s list for forms used without a shot](https://www.fda.gov/media/94155/download) The policy for forms that are not injected does not apply to GHK-Cu shots. - [FDA’s policy and its conditions for pharmacies](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) Ask the pharmacy to point to the conditions it relies on and explain how the proposed medicine meets them. - [A review of the wrinkle-product research](https://pubmed.ncbi.nlm.nih.gov/39963574/) The 2025 review found too few studies testing GHK-Cu wrinkle products in people, despite interest in experiments with cells. - [A small study after laser skin treatment](https://pubmed.ncbi.nlm.nih.gov/16847171/) In 2006, 13 people completed a study comparing skincare with GHK-Cu against skincare without it after laser treatment. - [What a search of ClinicalTrials.gov found](https://clinicaltrials.gov/api/v2/studies?query.term=GHK-Cu%20OR%20%22copper%20peptide%22%20OR%20%22copper%20tripeptide%22%20OR%20prezatide) ClinicalTrials.gov is a U.S. list where researchers enter details of studies in people. No GHK-Cu injection study was found there on September 30, 2026. That result covers one list on one day; it cannot rule out studies elsewhere. The small laser-treatment study did not find a clear measured benefit for redness, wrinkles or overall skin quality. That means the measurements did not give convincing evidence of a difference between the groups; it does not prove the treatments had identical effects. People who used the GHK-Cu skincare did report greater satisfaction. A study this small, on skin just treated with a laser, cannot settle every skin use. Too little research in people does not prove that GHK-Cu has no effect. Skin studies also cannot establish that shots help. A useful question for the prescriber Which study tested this ingredient as the cream or shot being offered, and did it measure the change you are promising me? Keep this thought Ask the person proposing treatment to show a study of the same ingredient, used the same way, for the same hoped-for result. [Take the question sheet with you →](/question-map/) The chapter index - [Opening map ↗ ](/) - [The whole bill ↗ ](/cost-map/) - [Insurance & payment ↗ ](/coverage-route/) - [Tests & lab bills ↗ ](/lab-map/) - [Care after the visit ↗ ](/follow-up-map/) - [Questions for a quote ↗ ](/question-map/) - [New York care checks ↗ ](/care-map/) - [Reasons to pause ↗ ](/risk-map/) - [GHK-Cu & the evidence ↗ ](/evidence-map/) This is a reading guide for peptide-care decisions, not a clinic, pharmacy or place that sells treatment. [Chapter index](#chapter-index) [Read this chapter as text](/evidence-map/index.md) [Text directory](/llms.txt)